Cover Image
市場調查報告書

全球偏頭痛藥市場

Global Migraine Market Report: 2016 Edition

出版商 Koncept Analytics 商品編碼 358169
出版日期 內容資訊 英文 45 Pages
訂單完成後即時交付
價格
Back to Top
全球偏頭痛藥市場 Global Migraine Market Report: 2016 Edition
出版日期: 2016年05月17日 內容資訊: 英文 45 Pages
簡介

本報告提供全球偏頭痛藥市場相關調查分析,以現狀與未來發展預測為焦點,提供市場規模,市場區隔分析,市場動態,加上競爭情形和主要企業等相關的系統性資訊。

第1章 市場概要

  • 簡介
  • 類型
  • 原因和病因
  • 症狀與診斷
  • 治療的選項

第2章 全球偏頭痛藥市場分析

  • 全球偏頭痛治療藥市場:各金額
  • 全球偏頭痛治療藥市場:各類別
  • 全球治療用肉毒桿菌市場:各金額
  • 全球治療用肉毒桿菌市場:各適應症

第3章 美國的偏頭痛藥市場

  • 美國的偏頭痛總人口
  • 美國的偏頭痛人口:各診斷
  • 美國的CV危險因素的偏頭痛人口
  • 美國的預防的偏頭痛治療:各專門科
  • 美國的急性偏頭痛治療人口:藥物的各類型
  • 美國的急性偏頭痛藥處方數量
  • 美國的急性偏頭痛藥的收益

第4章 市場動態

  • 成長推動因素
  • 趨勢
  • 課題

第5章 競爭情形

第6章 企業簡介

  • Amgen Inc.
    • 產業概要
    • 財務概要
    • 產業策略
  • Teva Pharmaceuticals
    • 產業概要
    • 財務概要
    • 產業策略
  • Eli Lilly and Company
    • 產業概要
    • 財務概要
    • 產業策略
  • AstraZeneca
    • 產業概要
    • 財務概要
    • 產業策略

圖表

目錄

Migraine is a common neurovascular disorder that is characterized by throbbing headaches and is commonly associated with other neurological symptoms, such as nausea, vomiting, and painful sensitivity to lights and sounds. Migraines are thought to result from the activation and sensitization of sensory neurons that have nerve endings in meningeal blood vessels. Migraines can be episodic or chronic. Chronic Migraine (CM) and Episodic Migraine (EM) are both part of the spectrum of migraine disorders, but are distinct clinical entities. The onset of migraine is preceded by certain triggers, which can be unique for each migraine sufferer.

Triptans and Ergots are among the most common drug options existing in the treatment market for migraine. The global migraine treatment market currently faces several unmet needs and is saturated with the availability of generic drugs. Several branded drugs are under development with safer and more effective profiles, given the vast opportunities existing in the market. The focus of upcoming drugs is to either cure migraine or to reduce the frequency to a level where patients can find tolerable relief.

The migraine market is expected to acquire modest growth driven by launch of new therapies and increasing rate of drug treatment due to increasing female population and rising awareness among physicians and patients. The major growth drivers of the migraine market includes rising spending on medicines, growing female population, increasing cigarette consumption and healthcare expenditure. However, the growth of the market will also remain challenged by complications associated with Triptans, treatment limitations for patients with CV (Cardio Vascular) risk and increased preference for OTC (Over the Counter) medications.

The report, “Global Migraine Market” analyzes the currently prevailing condition of the market along with its future scope of development. The specific market of the U.S. is being discussed in the report. The major trends, growth drivers as well as issues being faced by the industry are being presented in this report. The major players in the industry are being profiled, along with their key financials and strategies for growth.

Table of Contents

1. Market Overview

  • 1.1. Introduction
  • 1.2. Types
  • 1.3. Causes and Pathogenesis
  • 1.4. Symptoms and Diagnosis
  • 1.5. Treatment Options

2. Global Migraine Market

  • 2.1. Global Migraine Drug Market by Value
  • 2.2. Global Migraine Drug Market by Category
  • 2.3. Global Therapeutic Botulinum Toxin Market by Value
  • 2.4. Global Therapeutic Botulinum Toxin Market by Indication

3. The U.S. Migraine Market

  • 3.1. The U.S. Total Migraine Population
  • 3.2. The U.S. Migraine Population by Diagnosis
  • 3.3. The U.S. Migraine Population with CV Risk Factors
  • 3.4. The U.S Preventive Migraine Treatment by Specialty
  • 3.5. The U.S. Acute Migraine Treated Population by Drug Type
  • 3.6. The U.S. Acute Migraine Prescription Volume
  • 3.7. The U.S. Migraine Drugs Revenue
    • 3.7.1. Cambia
    • 3.7.2. Lasmiditan

4. Market Dynamics

  • 4.1. Growth Drivers
    • 4.1.1. Rising Spending on Medicines
    • 4.1.2. Growing Female Population
    • 4.1.3. Increasing Cigarette Consumption
    • 4.1.4. Rising Healthcare Expenditure
  • 4.2. Trends
    • 4.2.1. Emergence of Peripheral Nerve Stimulators
    • 4.2.2. Increased Preference for Non Pharmacological Treatment
    • 4.2.3. Higher Prevalence of Migraine than Other Chronic Diseases
    • 4.2.4. Recurrent Symptoms in Migraine Patients
    • 4.2.5. Drugs under Development for Migraine
  • 4.3. Challenges
    • 4.3.1. Complications associated with Triptans
    • 4.3.2. Treatment Limitations for Patients with Cardiovascular Disease
    • 4.3.3. Rise in Prescription Drugs to OTC Switch

5. Competitive Landscape

6. Company Profiles

  • 6.1. Amgen Inc.
    • 6.1.1. Business Overview
    • 6.1.2. Financial Overview
    • 6.1.3. Business Strategies
  • 6.2. Teva Pharmaceuticals
    • 6.2.1. Business Overview
    • 6.2.2. Financial Overview
    • 6.2.3. Business Strategies
  • 6.3. Eli Lilly and Company
    • 6.3.1. Business Overview
    • 6.3.2. Financial Overview
    • 6.3.3. Business Strategies
  • 6.4. AstraZeneca
    • 6.4.1. Business Overview
    • 6.4.2. Financial Overview
    • 6.4.3. Business Strategies

List of Charts

  • Global Migraine Drug Market by Value (2013-2020E)
  • Global Migraine Drug Market by Category (2015E)
  • Global Therapeutic Botulinum Toxin Market (2013-2020E)
  • Global Therapeutic Botulinum Toxin Market by Indication (2015)
  • The U.S. Total Migraine Population (2015-2022E)
  • The U.S. Migraine Population by Diagnosis (2015E)
  • The U.S. Migraine Population with CV Risk Factors (2015-2022E)
  • The U.S. Preventive Migraine Treatment by Specialty (2015)
  • The U.S. Acute Migraine Treated Population by Drug Type (2014)
  • The U.S. Acute Migraine Prescription Volume (2015-2025E)
  • The U.S. Cambia Drug Revenue (2015-2022E)
  • The U.S. Lasmiditan Drug Revenue & Treated Patient (2015-2022E)
  • Global Spending on Medicines (2010-2020E)
  • Pharmaceutical Spending Per Capita by Country (2015)
  • Global Female Population (2010-2015)
  • Global Cigarette Consumption (1910-2014)
  • Global Healthcare Expenditure (2010-2015E)
  • Global FDA Neuromodulator Trials by Category (2014)
  • Reasons for Initiation of VNS Therapy among Patients (2015)
  • Reasons for Continuation of VNS Therapy among Patients (2015)
  • Percentage of People Affected in the U.S. (2014)
  • Common Symptoms in Migraine Patients (2015)
  • Global Over the Counter (OTC) Drug Market (2010-2014)
  • Amgen Inc. Revenue Share by Geography (2015)
  • Amgen Inc. Revenue and Net Income (2011-2015)
  • Amgen Inc. Research and Development Expenditure (2011-2015)
  • Teva Pharmaceuticals Product Sales by Segment (2015)
  • Teva Pharmaceuticals Revenue and Net Income (2011-2015)
  • Teva Pharmaceuticals Research & Development Expenditure (2011-2015)
  • Eli Lilly Revenue by Segments (2015)
  • Revenue and Net Income of Eli Lilly and Company (2011-2015)
  • Research and Development Expenditure of Eli Lilly (2011-2015)
  • AstraZeneca Revenue by Therapeutic Segment (2015)
  • AstraZeneca Revenue by Regions (2015)
  • AstraZeneca Revenue and Net profit (2010-2015)

List of Tables

  • Common Migraine Triggers
  • Current Treatment Options for Moderate to Severe Episodic Migraine
  • Non-Triptans Migraine Drugs under Development
  • Global Migraine Competitors Comparison (2015)
  • Product and Other Acquisitions of Eli Lilly
Back to Top